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ABSTRACT We report the presence ofband 3 protein(s) in
mammalian brain that performs the same functions as those of
erythroid band 3. These functions are anion transport, ankyrin
binding, and generation of senescent cell antigen, an aging
antigen that terminates the life of cells. Structural similarity of
brain and erythroid band 3 is suggested by the reaction of
antibodies to synthetic peptides of erythroid band 3 with brain
band 3, the inhibition ofanion transport by the same inhibitors,
and an equal degree of inhibition of brain and erythrocyte
anion transport by synthetic peptides of erythroid band 3
(pep-ANION 2, residues 588-602; pep-COOH, residues 812-
827; pep-COOH-N6, residues 813-818). One ofthese segments,
pep-COOH, contains antigenic determinants of senescent cell
antigen. These findings suggest that the transport domains of
erythroid and neural band 3 are similar functionally and
structurally and support the hypothesis that the immunological
mechanism of maintaining homeostasis is a general physiologic
process for removing senescent and damaged cells in mammals
and other vertebrates.
The presence of band 3-related molecules in nonerythroid
tissues was first demonstrated in 1983 (1). A protein immu-
nologically related to band 3 was demonstrated in such
diverse cell types as isolated neurons, hepatocytes, squa-
mous epithelial cells, alveolar (lung) cells, lymphocytes,
neurons in vivo, and fibroblasts by using an antibody to band
3 that reacts with the transmembrane, anion transport domain
of band 3 (1). The band 3-like protein in many of these cell
types appeared to be a truncated version of the erythroid
protein based on its molecular mass of =60 kDa estimated
from its migration in polyacrylamide gels. We suggested that
part of the cytoplasmic amino terminus segment was missing
from the band 3-like protein in these cell types and that band
3 protein was modified to perform functions in different
environments (1). Since then, band 3 has been described in
numerous cell types and tissues, including fibroblasts, hep-
atoma cells, and lymphoid cells (2-6). Band 3 is also present
in nuclear (1), Golgi (7), and mitochondrial membranes (8) as
well as in cell membranes. Band 3-like proteins in nucleated
cells participate in band 3 antibody-induced cell surface
patching and capping (1). A truncated version of band 3,
which lacks the amino terminus, has also been described in
kidney (4, 5). Band 3 is present in the central nervous system,
and differences have been described in band 3 between young
and aging brain tissue (9). One autosomal recessive neuro-
logical disease, choreoacanthocytosis, is associated with
band 3 abnormalities (10, 11). The 150 residues of the
carboxyl terminus segment of band 3 appear to be altered
(11). In brains from Alzheimer disease patients, antibodies to
aged band 3 label the amyloid core of classical plaques and
the microglial cells located in the middle of the plaque in
tissue sections and an abnormal band 3 in immunoblots (9,
12). However, the question of whether band 3 in noneryth-
roid tissues performs the same functions as it does in eryth-
rocytes has not been addressed.
In erythrocytes, band 3 constitutes >30% of the total
membrane protein (13, 14). It maintains acid-base balance by
mediating the exchange of anions (e.g., chloride, bicarbon-
ate) (for review, see ref. 15) and contributes to respiration by
catalyzing CO2 exchange.
Degradation of band 3 generates senescent cell antigen, an
antigen of aging cells (16-26). Senescent cell antigen is
generated on the transport domain. Senescent cell antigen is
a protein that appears on old cells and acts as a specific signal
for the termination of that cell by initiating the binding of IgG
autoantibody and subsequent removal by phagocytes (16-
26). This appears to be a general physiologic process for
removing senescent and damaged cells in mammals and other
vertebrates (21). Although the initial studies were done with
human erythrocytes as a model, senescent cell antigen has
been found on all cells examined (21). Besides its role in the
removal of senescent and damaged cells, senescent cell
antigen also appears to be involved in the removal of eryth-
rocytes in clinical hemolytic anemias (24, 27) and the removal
of malaria-infected erythrocytes (28). Oxidation generates
senescent cell antigen in situ (23).
Since band 3 is such a crucial structural and functional
protein and is intimately involved in cellular aging, we
investigated its location, structure, and function in mamma-
lian brain. We then determined whether senescent cell anti-
gen, a terminal differentiation antigen, is generated in brain.
MATERIALS AND METHODS
Tissue Preparation and Immunohistochemical Analysis. Tis-
sue preparation and immunohistochemical analysis were
performed as described (29). Perfused brains from young
Sprague-Dawley rats were used for immunoblotting and
biochemical studies.
Brain and Erythrocyte Anion Transport. "Influx" and pep-
tide inhibition of sulfate influx experiments were performed
as described (12, 29, 30, 31).
Ankyrin Binding Studies. Binding of 125I-radiolabeled
ankyrin (2-20 ug/ml) to inside-out vesicles (40-60 pug/ml)
from erythrocytes or brain membranes depleted of cytoskel-
etal proteins by 0.1 M NaOH treatment was performed as
described (12, 32, 33). As an additional control, we performed
competitive inhibition studies with the 40-kDa cytoplasmic
segment of erythroid band 3.
NaDodSO4/Polyacrylamide Gel Electrophoresis and Immu-
nostaining of Membrane Proteins. Proteins were analyzed on
Abbreviation: DIDS, 4,4'-diisothiocyano-2,2'-disulfonic acid.
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FIG. 1. Antibodies to synthetic peptides ofhuman erythroid band 3 bind to band 3 from perfused rat brains in immunoblots. AB, amido black
stain for proteins; AR, autoradiograph. (Left) Lanes: R, erythrocyte membranes; B, brain membranes; a, amido black; b, antibodies to
pep-COOH (residues 812-827, Leu-Phe-Lys-Pro-Pro-Lys-Tyr-His-Pro-Asp-Val-Pro-Tyr-Val-Lys-Arg); c, antibodies to pep-CYTO (residues
122-144, Ala-Gly-Val-Ala-Asn-Gln-Leu-Leu-Asp-Arg-Phe-Ile-Phe-Glu-Asp-Gln). (Right) Lanes: a and c, erythrocyte membranes; b and d, brain
membranes; a and b, antibodies to pep-ANION 1, an external loop of band 3 containing a 4,4'-diisothiocyano-2,2'-disulfonic acid (DIDS) binding
site (residues 538-554, Ser-Lys-Leu-Ile-Lys-Ile-Phe-Gln-Asp-His-Pro-Leu-Gln-Lys-Thr-Tyr-Asn); c and d, antibodies prepared against a
mixture of the peptides COOH, CYTO, ANION 1, and ANION 2 (residues 588-602, Leu-Arg-Lys-Phe-Lys-Asn-Ser-Ser-Tyr-Phe-Pro-Gly-
Lys-Leu-Arg), an anion transport region.
6-25% or 12-25% linear NaDodSO4/polyacrylamide gradient
gels with a discontinuous buffer (34). Immunoautoradiogra-
phy was performed by the immunoblotting technique (1, 24,
34). The rabbit antibodies to whole human erythroid band 3
used (1, 24, 34) react with peptides from all segments of the
band 3 molecule including the carboxyl terminus.
IgG Binding and Inhibition Assay. Senescent cell IgG (3 jig)
was absorbed with brain membranes or purified senescent
cell antigen as described (19, 21) and incubated with an
indicator erythrocyte. The number ofIgG molecules bound to
the indicator erythrocyte was quantitated before and after
absorption by equilibrium binding kinetics (16, 17, 24, 34, 35).
RESULTS
Detection of Polypeptides Immunologically Related to Eryth-
roid Band 3 and Senescent Ceil Antigen in Immunoblots with
Antibodies to Human Erythroid Band 3 and Synthetic Peptides
ofBand 3. Antibodies to synthetic peptides ofhuman erythroid
band 3 reacted with band 3 and breakdown products of band
3 in erythrocyte membranes and multiple polypeptides immu-
nologically related to erythrocyte band 3 in membranes from
perfused rat brains (Fig. 1). Band 3 breakdown products have
been found to migrate in ranges between -5 and =85 kDa in
erythrocytes (21-26). Some of the band 3 antibody reactive
bands migrating at different molecular masses in brain may be
FIG. 2. Antibodies to syn-
thetic peptides ofhuman erythroid
band 3 react with frozen sections
of mouse and human brain as de-
tected with rhodamine staining.
(A-C) Human cerebellum stained
with antibodies to pep-CYTO. (A)
Internal granular layer showing
staining of glomeruli (GLOM) and
granule cells (IGC). (B) Pia and
subjacent molecular layer (MOL).
(C) Control consisting of antisera
absorbed with the peptide. (D-F)
Mouse brain stained with antibod-
ies to synthetic peptides from two
external loops of band 3 (16, 17).
(D) Ependyma of the fourth ven-
tricle stained with antibodies to
pep-ANION 1. (E) Choroid
plexus of the fourth ventricle
stained with antibodies to pep-
COOH. (F) Control consisting of
antisera absorbed with pep-
COOH peptide.
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Table 1. Inhibition of senescent cell IgG binding by senescent
cell antigen from erythrocytes or perfused rat brain
Sample Inhibition, %
Control cytoplasmic peptide 0
Senescent cell antigen 74 ± 6*
Brain (perfused) 80 ± 2*
Data are presented as the mean ± 1 SD of quadruplicate samples.
Erythrocytes were separated into populations of different ages on
Percoll gradients as described (20). Middle-aged cells were stored at
40C for 3 weeks in Alsever's solution. Storage mimics normal aging
in situ both immunologically and biochemically (16-26). Senescent
cell IgG was isolated from senescent erythrocytes as described (21)
and 3 ,ug was incubated with senescent cell antigen from erythro-
cytes, perfused rat brain, or buffer for 90 min at room temperature.
Intact erythrocytes were added to the IgG and samples were incu-
bated for 90 min at room temperature. Cells were washed and the
amount of IgG on cells was quantitated with 1251I-labeled protein A
(16, 17, 24, 35). Control cytoplasmic peptide is the band 3 peptide
pep-CYTO.
*P - 0.001.
brain band 3 breakdown products. However, some of these
bands probably represent different forms of band 3 in brain
membranes because the brains were snap frozen and homog-
enized in a buffer containing the following protease inhibiting
agents: EGTA, leupeptin, pepstatin, aprotinin, KF, 2-mercap-
toethanol, phenylmethylsulfonyl fluoride, and diisopropylflu-
orophosphate (12, 29). We suspect that there are multiple
forms of band 3 protein that are adapted to various functions
in neural and other tissue. There may be more than one type
ofband 3 in a cell type or different cell types may have different
band 3 molecules. This requires further study.
Binding of antibodies to synthetic peptides of erythroid
band 3 to brain membranes suggests that the primary struc-
ture of these segments that is recognized by the antibodies is
similar in brain and erythrocytes. Senescent cell antigen has
been mapped to erythroid band 3 residues 538-554 and
812-827 (16, 17).
IgG eluted from senescent erythrocytes binds to band 3 in
erythrocytes and band 3-related polypeptides in membranes of
saline-perfused rat brains as determined by immunoblotting
(data not shown). Absorption of senescent cell IgG with brain
membranes resulted in inhibition ofbinding in the IgG binding/
inhibition assay (80%o + 2%; Table 1). For comparison, ab-
sorption with purified erythroid senescent cell antigen itself
resulted in a74% ± 6% inhibition ofbinding. This suggests that
senescent cell antigen is generated on brain band 3.
Immunohistochemical Localization of Band 3-like Proteins
in Brain with Antibodies to Erythroid Band 3 and Synthetic
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FIG. 3. Antibodies to human erythroid band 3 bind to human and
mouse brain band 3 in frozen sections visualized with peroxidase
staining. (A) Purkinje cell (PC) in human cerebellum. Basket fibers
(BF), which are located in the molecularlayer, are wrapped around the
soma and primary dendrite of the Purkinje cell. The internal granule
layer is subadjacent to the Purkinje cell at the bottom of the photo-
graph. (B) Neural cells in mouse cerebellar cortex. Granule cells (IGC)
and glomeruli (GLOM) (areas of synaptic contact) stain with antibod-
ies to band 3. (C) Control section of human brain incubated with
preimmune serum. The same results as those shown in C were
obtained when antisera was absorbed with erythrocyte band 3. (x80.)
Peptides ofHuman Erythroid Band 3. Antibodies to the whole
band 3 molecule and to synthetic peptides stained Purkinje
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FIG. 4. Quantitation of DIDS binding sites on brain membranes. Tritiated DIDS was used to quantitate the number of band 3 molecules per
mg of protein as described (12). B, bound; F, free. B.., 1500 ± 255 pmol per mg of protein; Kd, 10.7 ± 1 mM. This suggests that DIDS binding
sites constitute -14% oftotal brain membrane protein based on a molecular mass of95 kDafor band 3. The calculation is based on the assumption
that all band 3 molecules in brain bind DIDS and each band 3 binds a single DIDS molecule. This assumption is correct for erythrocytes.
However, the proportion ofband 3 in brain needs to be examined further because our data suggest that band 3like proteins in brain have different
molecular masses, and DIDS may label all neural anion transporters, not just band 3.
2780 Cell Biology: Kay et al.
411
Proc. Natl. Acad. Sci. USA 88 (1991) 2781
cell soma, axons, glomeruli (areas of synaptic contact) in the
pia, internal granular layer, ependymal cells lining the ven-
tricles, and the choroid plexus as determined by rhodamine
and peroxidase staining (Figs. 2 and 3). The presence ofband
3 in the choroid plexus is not surprising given the transport
properties of this epithelium, which maintains the chemical
stability of the cerebrospinal fluid.
Ankyrin Binding. Erythrocyte band 3 binds to ankyrin,
which anchors it to spectrin. Therefore, we examined the
interaction between brain band 3 and erythrocyte ankyrin.
Ankyrin binding studies gave the following results: n = 16 +
3 pcg ofankyrin per mg ofprotein after removal ofcytoskeletal
proteins; Kd = 33 + 5 nM. The 40-kDa cytoplasmic segment
of erythroid band 3 competed with brain band 3 and reduced
ankyrin binding to brain membranes by 58%. This indicates
that -58% of the ankyrin binding is to band 3. Thus, brain
band 3 appears to perform the same structural function of
stabilizing the plasma membrane and linking it to the internal
cytoskeleton as does erythrocyte band 3.
Quantitation of Band 3 Molecules. Band 3 molecules were
quantitated on brain membranes with radioactive DIDS (Fig.
4).
Anion Transport Studies. Anion transport studies were
performed on cerebral cortex by both the tube and the
chamber techniques (Fig. 5). The presence of DIDS in-
hibitable anion transport systems in brain was detected by
both methods.
We compared the effect of the anion transport inhibitors
DIDS, phenylglyoxal, and furosemide on brain and erythro-
cyte anion transport (Fig. 6). Sulfate exchange is inhibited in
erythrocytes by DIDS, phenylglyoxal, and furosemide. Stil-
benedisulfonate derivatives such as DIDS inhibit anion trans-
port by binding to at least two lysine residues in the mem-
brane-spanning region of band 3 (18, 19). DIDS is a specific,
irreversible inhibitor of anion transport. It binds covalently.
Phenylglyoxal modifies an arginine involved-in anion trans-
port that is located on the 35-kDa carboxyl segment of band
3 (see ref. 23). The diuretic furosemide inhibits NaCl cotrans-
port by acting at a chloride transport site. The compounds
that inhibit anion transport in erythrocytes also inhibit trans-
port in brain. Transport by brain vesicles was reduced to a
level =74% of normal by DIDS, to =65% by furosemide, and
to =45% by phenylglyoxal (Fig. 6). In contrast, transport in
erythrocytes was reduced 100% by DIDS and =95% by
furosemide. Inhibition by phenylgloxal was the same for
brain and erythrocytes. Since brain anion transport was
significantly inhibited but not abolished by DIDS, the data
suggest the presence in brain of more than one anion trans-
port system [i.e., a transport system(s) that is DIDS in-
hibitable and another or others that are not] and/or that
=20% of the sulfate influx is due to leakage. There may be
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FIG. 5. Anion transport by brain membrane vesicles measured by
the tube method (A) and the chamber method (B). Transport: tube,
385 ± 20 nmol per min per mg of protein without DIDS; 199 ± 34
nmol per min per mg with 25 mM DIDS; chamber, 17.7 ± 4.8 fmol
per min per mg of protein without DIDS; 10.4 ± 0.9 fmol per min per
mg of protein with 25 mM DIDS. Inhibition is 48% ± 9o by the tube
method and 41% ± 5% by the chamber method. In the chamber
method, radioactive substratelis added and buffer is pumped through
the lower chamber at a constant rate with a Pharmacia pump (model
P-1) connected to a LKB fraction collector. Fractions of 0.55 ml are
collected directly into scintillation vials. At the beginning of fraction
20, 20 1. of either buffer or membrane vesicles (0.5-7.5 mg per ml of
protein) is added to the upper chamber and 20 more fractions are
collected. The experiment is carried out at 230C. o, Control; o,
DIDS.
many transporters in each cell type present in the brain or
there may be different transporters in different cell types. We
suspect that the former is the case. However, the next
obvious step is to examine pure cell types from brain tissue.
Peptide Inhibition of Anion Transport. Peptides from pu-
tative human erythroid transport regions were used to inhibit
sulfate transport into erythrocytes and brain vesicles (F7).
Peptides used were pep-ANION 1, pep-ANION 2, pep-
COOH, and pep-COOH-N6. pep-COOH-6 is on the amino
0O'
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FIG. 6. Anion transport inhibi-
tion of erythrocyte (Left) or brain
(Right) anion transport by the an-
ion transport inhibitors DIDS,
phenylglyoxal (PG), furosemide
(FM), DIDS and PG, or DIDS and
FM. Results are plotted as the
mean + SD.
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end ofpep-COOH and contributes a significant amount of the
antigenicity of senescent cell antigen (16). In previous ex-
periments, we have shown that pep-ANION 1, a putative
transport region, does not inhibit anion transport in erythro-
cytes (17, 36). Thus, it serves as a negative control for these
experiments. Results of these experiments showed that the
same peptides that inhibited anion transport in erythrocytes
inhibit transport in brain (Fig. 7). This suggests that the
transport sites in erythroid and neural tissue are similar.
DISCUSSION
Analogues to erythrocyte membrane cytoskeletal proteins
have been found in most if not all tissues throughout the body
(33, 37, 38). Thus, the proteins with which band 3 interacts in
erythrocytes to provide structural stability to the membrane
are present in neural tissue.
The results of these studies indicate that one or more band
3 proteins are present in mammalian brain that perform the
same functions as that of erythroid band 3. These functions
are anion transport, ankyrin binding, and generation of
senescent cell antigen, an aging antigen that terminates the
life of cells. The anion transport segments of erythroid and
brain band 3 must be similar since synthetic peptides from
transport regions of erythroid band 3 inhibit anion transport
by brain vesicles as well as erythrocytes. In addition, the
inhibitors of anion transport in erythrocytes (DIDS, phenyl-
gloxal, and furosemide) also inhibit anion transport by brain
membranes. Since senescent cell antigen is derived from
band 3 and (i) IgG specific for this antigen binds to brain
membranes in immunoblots and a senescent cell IgG binding-
inhibition assay, and (ii) antibodies to the segments of band
3 on which senescent cell antigen resides react with brain in
immunoblots and tissue sections, the data suggest that se-
nescent cell antigen may be involved in the removal of
neurons in aging and disease. This supports the hypothesis
that the immunological mechanism of maintaining homeosta-
sis is a general physiologic process for removing senescent
and damaged cells in mammals and other vertebrates (21).
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